One of the first 11 patients to receive CRISPR Therapeutics’ anti-CD19 allogeneic CAR-T cell therapy has died. The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,